The firm said that the funding may be used to support further development of its portfolio of diagnostics for sepsis-causing pathogens and antibiotic-resistance genes.
Abionic will conduct all premarket process requirements for the test, while Genentech will fund the clinical and regulatory costs associated with the test.
The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.
Chembio said it will receive funding subject to satisfying milestones to develop a test that leverages its immunoassay platform and hand-held optical analyzer.
Chembio said it will receive funding to develop a test that combines its Dual Path Platform (DPP) technology with a Perseus concussion biomarker.
The two organizations will first focus on developing and validating Breath Diagnostics' OneBreath platform for lung cancer.
Group K said that the partners are developing a RT-LAMP system for use at the point of care in resource-limited areas where real-time RT-PCR is not available.
The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.
The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.